Merck & Co sells ophthalmic brands and Colorado biologicals unit

13 May 2014
mergers-acquisitions-big

US pharma giant Merck & Co (NYSE: MRK) has entered into two more divestment transactions, following the recent sell-off of its consumer business to Bayer for $14.2 billion (The Pharma Letter May 6), the firm is divesting a number of ophthalmic brands to Japan’s Santen Pharmaceuticals (TYO: 4536) in certain regions, and will also sell its Colorado-based biologicals manufacturing facility to KBI Biopharma.

The sales territories are Japan, Europe, and Asia Pacific, and annual sales in these markets associated with these ophthalmic products are around $400 million and include brands such as Cosopt (dorzolamide) and Timoptic (timolol maleate). Merck divested its US ophthalmology business to Akorn Pharmaceuticals in 2013 and 2014. It will continue to sell its eye products in Latin America, Canada, Australia, the Middle East, Africa and other markets.

Under the terms of the agreement, Santen will make an upfront payment of around $600 million and additional payments based on defined sales milestones as needed. Santen will also receive supply from Merck, the ophthalmology products within this agreement for a two to five year period.

“The decision to divest our ophthalmics business is part of our ongoing strategy to sharpen our commercial focus and improve our operational effectiveness,” said Jay Galeota, president, Hospital and Specialty Care, at Merck, adding: “This transaction provides products that complement Santen’s portfolio and is designed to ensure continued access for physicians and patients to these medicines around the world.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical